The French Competition Authority announced its approval for a pending merger between pharmaceutical giants Actavis and Warner Chilcott, say reports. Actavis’s buyout of Warner Chilcott remains pending. The German Federal Cartel Office has similarly cleared the deal and, according to a press release, the parties have now obtained permission from all ex-US antitrust regulators. Financial details of the deal were not made public. Actavis, based in the US, recently went head-to-head with the US Federal Trade Commission in the Supreme Court; the Court found that so-called pay-for-delay deals, which delay cheaper, generic forms of pharmaceuticals from being sold, can be subject to antitrust lawsuits.
Featured News
EU Digital Sovereignty Debate Intensifies Over CAIDA’s Scope
Jun 15, 2026 by
CPI
OnlyFans Software Firm Rejects Antitrust Allegations in Data Access Dispute
Jun 15, 2026 by
CPI
Community Resistance Emerges as Major Obstacle to US Data Center Expansion: Report
Jun 15, 2026 by
CPI
UK Moves Toward ‘Australia-Plus’ Social Media Ban for Children Under 16
Jun 15, 2026 by
CPI
Nuvei to Acquire Payoneer in $2.75 Billion Payments Deal
Jun 15, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani